NNVC - NanoViricides, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc.

NNVC 1.120

-7.4%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Colavita365 who wrote (12095)	4/2/2019 4:59:40 PM
From: HardToFind	Read Replies (1) of 12873

The company should hedge its bets and go with the easiest path to drug approval for its topical product, and not necessarily have a one-track mind about just shingles. Genital herpes may actually be a lower regulatory bar to jump over than shingles, given the limitations of a topically applied product for a disease with origins deep within the body. I completely agree, but what about Anil Diwan's $4 Mn entitlement for licensing the shingles indication. Sadly, I'm concerned that's going to unduly influence the decision because it has already unduly influenced the path this company has taken. We spent a year or more getting the Moffat model validated, which wouldn't have been necessary if we had just gone for HSV-1 and HSV-2. Seymour was pushing for initially going out with an HSV-1/HSV-2 indication when he was CEO, but Diwan would have none of it. I'm afraid we are at the mercy of the whims of an egomaniac who will get his $4 Mn licensing fee, whether it is in the best interest of the company or not.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next